Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Efficient in vitro screening for drug combinations: The TEVA model

Dr Angel Porgador - Ben-Gurion University of the Negev, Beersheeba, Israel

Efficient in vitro screening for drug combinations: The TEVA model ( Dr Angel Porgador - Ben-Gurion University of the Negev, Beersheeba, Israel )

Systems immunology in immuno-oncology

Dr Nikesh Kotecha - Parker Institute for Cancer Immunotherapy, San Francisco...

Systems immunology in immuno-oncology ( Dr Nikesh Kotecha - Parker Institute for Cancer Immunotherapy, San Francisco, USA )

Innovation in clinical trials: WINTHER trial

Prof Razelle Kurzrock - University of California San Diego, San Diego, USA

Innovation in clinical trials: WINTHER trial ( Prof Razelle Kurzrock - University of California San Diego, San Diego, USA )

A precision medicine approach to therapeutic resistance using KEAP1 somatic...

Dr Gerald Batist - McGill University - Segal Cancer Centre, Montreal, Canada

A precision medicine approach to therapeutic resistance using KEAP1 somatic mutations ( Dr Gerald Batist - McGill University - Segal Cancer Centre, Montreal, Canada )

Gene expression in primary non-small cell lung cancer as a predictor of brain...

Dr Jair Bar - Sheba Medical Center, Tel Hashomer, Israel

Gene expression in primary non-small cell lung cancer as a predictor of brain metastases ( Dr Jair Bar - Sheba Medical Center, Tel Hashomer, Israel )

Rewriting the code of life: CRISPR-Cas9 genome editing

Prof Jennifer Doudna - University of Berkeley, Berkeley, USA

Rewriting the code of life: CRISPR-Cas9 genome editing ( Prof Jennifer Doudna - University of Berkeley, Berkeley, USA )

Direct targeting of STAT3 alone and in combination with immune checkpoint...

Dr David Tweardy - The University of Texas MD Anderson Cancer Center, Houston...

Direct targeting of STAT3 alone and in combination with immune checkpoint inhibitors to treat solid tumours ( Dr David Tweardy - The University of Texas MD Anderson Cancer Center, Houston, USA )

Integration of DNA and RNA investigations in clinical trials: A laboratory...

Brandon Young - Bowden WIN Precision Oncology Laboratory, Murrieta, USA

Integration of DNA and RNA investigations in clinical trials: A laboratory challenge ( Brandon Young - Bowden WIN Precision Oncology Laboratory, Murrieta, USA )

Optimising patient enrolment and efficacy of precision oncology clinical trials

Prof Apostolia-Maria Tsimberidou - The University of Texas MD Anderson Cancer...

Optimising patient enrolment and efficacy of precision oncology clinical trials ( Prof Apostolia-Maria Tsimberidou - The University of Texas MD Anderson Cancer Center, Houston, USA )

Comment: POLO III trial for metastatic pancreatic cancer

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Comment: POLO III trial for metastatic pancreatic cancer ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T...

Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy ( Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients...

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )

More from ecancer